CJC-1295 with DAC vs Tesamorelin

At a glance

CJC-1295 with DAC

A tetrasubstituted GHRH(1-29) analog bearing a Drug Affinity Complex, which binds serum albumin and dramatically extends circulating half-life versus the no-DAC form.

CJC-1295 with DAC is a synthetic peptide with the molecular formula C165H269N47O46 and a molecular weight of 3647.15 g/mol, CAS registry number 863288-34-0. The vial is sealed and lot-numbered, holds lyophilised powder, and is kept at −20°C protected from light until it ships.

CJC-1295 is an analog of the first 29 residues of growth-hormone-releasing hormone. DAC stands for Drug Affinity Complex, a chemical modification that lets the molecule bind serum albumin and circulate far longer than the unmodified peptide. The DAC and non-DAC forms are distinct compounds.

The 2 papers cited below are 2 studies in humans.

Cited on the CJC-1295 with DAC page

1. Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PubMed 16352683 · SummaryHealthy adults: a single dose raised growth hormone for at least six days and IGF-1 for nine to eleven days; estimated half-life 5.8–8.1 days.
2. Ionescu M & Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. PubMed 17018654 · SummaryGrowth hormone remained pulsatile under CJC-1295: trough and mean levels rose while pulse frequency was unchanged.

Tesamorelin

A 44-amino-acid GHRH analog stabilised against enzymatic degradation. The most clinically characterised growth hormone releasing hormone in research use.

Tesamorelin is a synthetic peptide with the molecular formula C221H366N72O67S and a molecular weight of 5135.86 g/mol, CAS registry number 218949-48-5. The vial is sealed and lot-numbered, holds lyophilised powder, and is kept at −20°C protected from light until it ships.

Tesamorelin is a growth-hormone-releasing-hormone analog. A pharmaceutical form is FDA-approved under the name Egrifta for one specific indication. The research vial sold here is not that product and is not manufactured to its standard.

The 3 papers cited below are 3 studies in humans.

Cited on the Tesamorelin page

1. Falutz J et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. PubMed 18057338 · SummaryHIV patients with abdominal fat accumulation, 26 weeks: visceral adipose tissue fell about 15% against a rise on placebo.
2. Falutz J et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. PubMed 20554713 · SummaryPooled analysis of two phase 3 trials: the visceral fat reduction held through 52 weeks of continued treatment and reversed on withdrawal.
3. Stanley TL et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. PubMed 31611038 · SummaryTwelve-month trial in HIV-associated liver fat: hepatic fat fraction fell and fewer participants progressed in fibrosis.

Handling the two side by side

CJC-1295 with DAC

• Lyophilised powder is stable for years at −20°C in the dark and tolerates days at ambient temperature in transit.

Tesamorelin

• Lyophilised powder is stable for years at −20°C in the dark and tolerates days at ambient temperature in transit.

Where to go next

• CJC-1295 with DAC and Tesamorelin: full specifications, stability notes, references and the certificate for the lot in stock.
• CJC-1295 with and without DAC: how the whole group compares.
• How to read a certificate of analysis and the certificates page.